Literature DB >> 9213302

Non-small cell lung cancer: clinical value of new biological predictors.

S L Graziano1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213302     DOI: 10.1016/s0169-5002(97)00639-9

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  8 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 2.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Authors:  Simona Carnio; Silvia Novello; Mauro Papotti; Marco Loiacono; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Hisao Imai; Kimihiro Shimizu; Noriko Yanagitani; Noriaki Sunaga; Takeshi Hisada; Osamu Kawashima; Yosuke Kamide; Tamotsu Ishizuka; Yoshikatsu Kanai; Takashi Nakajima; Masatomo Mori
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

4.  Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases.

Authors:  T Fukuse; T Hirata; H Naiki; S Hitomi; H Wada
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

5.  FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value.

Authors:  Marina Suárez-Piñera; José Belda-Sanchis; Alvaro Taus; Albert Sánchez-Font; Antoni Mestre-Fusco; Marcel Jiménez; Lara Pijuan
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

6.  Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.

Authors:  M Essler; J Wantke; B Mayer; K Scheidhauer; R A Bundschuh; B Haller; S T Astner; M Molls; N Andratschke
Journal:  Strahlenther Onkol       Date:  2013-04-24       Impact factor: 3.621

7.  SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.

Authors:  Yoo-Kang Kwak; Hee Hyun Park; Kyu Hye Choi; Eun Young Park; Soo Yoon Sung; Sea-Won Lee; Ji Hyun Hong; Hyo Chun Lee; Ie Ryung Yoo; Yeon Sil Kim
Journal:  Cancer Res Treat       Date:  2019-05-17       Impact factor: 4.679

8.  Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy.

Authors:  Hyun-Cheol Kang; Hong-Gyun Wu; Tosol Yu; Hak Jae Kim; Jin Chul Paeng
Journal:  Radiat Oncol J       Date:  2013-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.